Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies Pharmaceutical Investing
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines Pharmaceutical Investing
The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery Pharmaceutical Investing
LYNPARZA® Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient -Positive Advanced Ovarian Cancer Life Science Investing
Pfizer to Supply Global Fund Up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries Life Science Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
